Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) rose 4.3% during mid-day trading on Wednesday . The stock traded as high as $55.14 and last traded at $54.69, with a volume of 161,309 shares changing hands. The stock had previously closed at $52.45.

ONCE has been the subject of several recent research reports. Zacks Investment Research raised Spark Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Wednesday, April 20th. Goldman Sachs Group Inc. initiated coverage on Spark Therapeutics in a report on Wednesday, March 30th. They set a “neutral” rating and a $44.00 price target for the company. Evercore ISI initiated coverage on Spark Therapeutics in a report on Tuesday, April 12th. They set a “buy” rating and a $37.00 price target for the company. Wedbush reissued an “underperform” rating and set a $21.00 price target on shares of Spark Therapeutics in a report on Thursday, May 19th. Finally, Chardan Capital reissued a “neutral” rating on shares of Spark Therapeutics in a report on Thursday, April 14th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. Spark Therapeutics presently has a consensus rating of “Hold” and an average price target of $59.70.

The stock’s market cap is $1.49 billion. The company has a 50 day moving average price of $51.44 and a 200-day moving average price of $38.70.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, May 4th. The company reported ($0.95) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.11. The firm had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $1.48 million. The business’s revenue for the quarter was down 43.2% on a year-over-year basis. Analysts anticipate that Spark Therapeutics Inc. will post ($3.84) EPS for the current fiscal year.

In other news, CFO Stephen W. Webster sold 20,000 shares of Spark Therapeutics stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the sale, the chief financial officer now owns 22,500 shares of the company’s stock, valued at approximately $1,133,775. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Coelho Rogerio Vivaldi sold 7,000 shares of Spark Therapeutics stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $40.02, for a total transaction of $280,140.00. Following the sale, the insider now directly owns 19,716 shares in the company, valued at approximately $789,034.32. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Spark Therapeutics stock. TD Asset Management Inc. boosted its stake in shares of Spark Therapeutics Inc. (NASDAQ:ONCE) by 72.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,187 shares of the company’s stock after buying an additional 24,400 shares during the period. TD Asset Management Inc. owned about 0.24% of Spark Therapeutics worth $2,636,000 as of its most recent filing with the SEC.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.